Literature DB >> 24930042

Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.

F D Wang1, C H Liao, Y T Lin, W H Sheng, P R Hsueh.   

Abstract

We investigated the antimicrobial resistance trends and profiles of clinical anaerobic isolates in northern Taiwan. Trends in the susceptibility of five commonly encountered clinical anaerobic isolates to seven agents from 2008 to 2012 were measured using the Cochran-Armitage trend test. The minimum inhibitory concentrations (MICs) of 16 antimicrobial agents, including fidaxomicin and rifaximin, against anaerobic blood isolates from two medical centers were determined using the agar dilution method. During the study period, susceptibility data on 11,105 isolates were evaluated. Metronidazole and chloramphenicol retained excellent activities. Around 20-30 % of isolates of Bacteroides and Prevotella species were resistant to ampicillin-sulbactam, cefmetazole, flomoxef, and clindamycin. Of the 507 tested blood isolates, the rates of resistance to commonly used agents were much higher, namely, 16.2 % for amoxicillin-clavulanate, 15.6 % for ampicillin-sulbactam, 24.7 % for cefmetazole, and 36.1 % for clindamycin. Notably, 13.5 % of B. fragilis isolates were resistant to ertapenem. Also, 15.2 % of B. uniformis, 17.2 % of other Bacteroides species, 14.3 % of Prevotella species, and 14 % of Clostridium other than C. perfringens isolates were resistant to moxifloxacin. Cefoperazone-sulbactam was active against most isolates, except for Clostridium species other than perfringens (resistance rate, 18.6 %). Fidaxomicin exerted poor activities against most anaerobes tested (MIC90 of >128 μg/ml for B. fragilis and all isolates), except for C. perfringens (MIC90 of 0.03 μg/ml) and Peptostreptococcus micros (MIC90 of 2 μg/ml). However, rifaximin showed a wide range of susceptibilities against the tested anaerobes (MIC90 of 0.5 μg/ml for B. fragilis). The emergence of resistance to ertapenem and moxifloxacin among bacteremic anaerobes highlights the need for continuous monitoring.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24930042     DOI: 10.1007/s10096-014-2175-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  The status of research on anaerobes in Japan.

Authors:  Kazue Ueno; Naoki Kato; Haru Kato
Journal:  Clin Infect Dis       Date:  2002-09-01       Impact factor: 9.079

2.  Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.

Authors:  J Papaparaskevas; A Pantazatou; A Katsandri; N J Legakis; A Avlamis
Journal:  Clin Microbiol Infect       Date:  2005-10       Impact factor: 8.067

3.  Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Authors:  D R Snydman; N V Jacobus; L A McDermott; Y Golan; E J C Goldstein; L Harrell; S Jenkins; D Newton; C Pierson; J Rosenblatt; R Venezia; S L Gorbach; A M Queenan; D W Hecht
Journal:  Anaerobe       Date:  2011-06-02       Impact factor: 3.331

4.  Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe.

Authors:  Anna King; Julie Downes; Carl-Erik Nord; Ian Phillips
Journal:  Clin Microbiol Infect       Date:  1999-07       Impact factor: 8.067

5.  Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey.

Authors:  J Sóki; R Edwards; M Hedberg; H Fang; E Nagy; C E Nord
Journal:  Int J Antimicrob Agents       Date:  2006-11-13       Impact factor: 5.283

6.  Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Authors:  Ingrid Wybo; Denis Piérard; Inge Verschraegen; Marijke Reynders; Kristof Vandoorslaer; Geert Claeys; Michel Delmée; Youri Glupczynski; Bart Gordts; Margaretha Ieven; Pierrette Melin; Marc Struelens; Jan Verhaegen; Sabine Lauwers
Journal:  J Antimicrob Chemother       Date:  2006-11-09       Impact factor: 5.790

7.  Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  S M Finegold; D Molitoris; M-L Väisänen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents.

Authors:  Laura M Koeth; Caryn E Good; Peter C Appelbaum; Ellie J C Goldstein; Arne C Rodloff; Marina Claros; Luc J Dubreuil
Journal:  J Antimicrob Chemother       Date:  2004-05-05       Impact factor: 5.790

10.  High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.

Authors:  Lee-Jene Teng; Po-Ren Hsueh; Jui-Chang Tsai; Shwu-Jen Liaw; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more
  6 in total

1.  Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.

Authors:  Chien-Ming Chao; Chih-Cheng Lai; Chen-Hsiang Lee; Hung-Jen Tang
Journal:  Antibiotics (Basel)       Date:  2022-04-30

2.  Activation of Bacteroides fragilis toxin by a novel bacterial protease contributes to anaerobic sepsis in mice.

Authors:  Vivian M Choi; Julien Herrou; Aaron L Hecht; Wei Ping Teoh; Jerrold R Turner; Sean Crosson; Juliane Bubeck Wardenburg
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

3.  Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials.

Authors:  Takumi Kawaguchi; Fumitaka Suzuki; Masatoshi Imamura; Naoya Murashima; Mikio Yanase; Tetsuya Mine; Masaki Fujisawa; Ikuya Sato; Hitoshi Yoshiji; Kiwamu Okita; Kazuyuki Suzuki
Journal:  Hepatol Res       Date:  2019-02-01       Impact factor: 4.288

Review 4.  Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.

Authors:  Huanna Tang; Hui Zhou; Runju Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-27       Impact factor: 6.073

5.  Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait.

Authors:  Wafaa Jamal; Fatima Bibi Khodakhast; Ameerah AlAzmi; Jόzsef Sόki; Ghayda AlHashem; Vincent O Rotimi
Journal:  BMC Microbiol       Date:  2020-01-15       Impact factor: 3.605

6.  Phenotypic and genotypic antimicrobial resistance in clinical anaerobic isolates from India.

Authors:  Anshul Sood; Pallab Ray; Archana Angrup
Journal:  JAC Antimicrob Resist       Date:  2021-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.